Φορτώνει......
Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could b...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | BMC Urol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BioMed Central
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8247203/ https://ncbi.nlm.nih.gov/pubmed/34210300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-021-00856-x |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|